This is the authors' abstract. We don't add key points for this paper.
dd-cfDNA may be a useful dynamic biomarker to assess the health of the kidney allograft following rejection treatment.
No takes yet. Share an insight, caveat, or question.
Wolf‐Doty et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: